| 12/12/2018 |
CDY- Cellmid Expects Record Sales in Q2 FY2019 |
| 19/11/2018 |
CDY – Cellmid Appoints Exclusive New Zealand Distributor |
| 13/11/2018 |
CDY – Change of Directors Interest Notice – Eck |
| 13/11/2018 |
CDY – Change of Directors Interest Notice – Halasz |
| 12/11/2018 |
Appendix 3B and Cleansing Notice |
| 08/11/2018 |
AGM Presentation to Shareholders |
| 08/11/2018 |
Results of Annual General Meeting |
| 07/11/2018 |
New Patents for Midkine Antibodies in USA and Europe |
| 02/11/2018 |
Ikon Legal Action – Decision |
| 02/11/2018 |
Trading Halt |
| 01/11/2018 |
Cellmids Evolis Successfully Launched in USA stores |
| 01/11/2018 |
Repayment of R&D Loan |
| 31/10/2018 |
Investor Presentation |
| 30/10/2018 |
Cellmid receives R&D tax credit |
| 15/10/2018 |
Appendix 4C and Notes to Appendix 4C |
| 09/10/2018 |
Appendix 4C and Notes to Appendix 4C |
| 08/10/2018 |
Appendix 3B and Cleansing Notice |
| 03/10/2018 |
Appendix 3B |
| 03/10/2018 |
Cleansing Notice |
| 28/09/2018 |
Appendix 3B |
| 28/09/2018 |
Change of Registry Address: Automic P/L – Sydney Office |
| 27/09/2018 |
Annual Report to Shareholders 2018 |
| 27/09/2018 |
Appendix 4G and Corporate Governance Statement |
| 25/09/2018 |
Change of Director’s Interest Notice_Bruce Gordon |
| 24/09/2018 |
Clarification Announcement |
| 21/09/2018 |
CDY Investor Newsletter – 21 September 2018 |
| 19/09/2018 |
Date of Annual General Meeting |
| 19/09/2018 |
Full Year Statutory Accounts |
| 14/09/2018 |
Becoming a Substantial Holder |
| 13/09/2018 |
Change of Director’s Interest Notice_Cross |
| 13/09/2018 |
Change of Director’s Interest Notice_Eck |
| 13/09/2018 |
Change of Director’s Interest Notice_Gordon |
| 13/09/2018 |
Change of Director’s Interest Notice_Halasz |
| 12/09/2018 |
Appendix 3B |
| 12/09/2018 |
Cellmid’s Lead Antibody Effective in Rare Chronic Kidney Disease |
| 12/09/2018 |
Cleansing Notice |
| 07/09/2018 |
EGM Presentation by CEO |
| 07/09/2018 |
Results of the Extraordinary General Meeting of Members |
| 06/09/2018 |
Appointment and Resignation of Company Secretary |
| 03/09/2018 |
Cellmid Share Purchase Plan Completion |
| 30/08/2018 |
Evolis USA Distribution Update |
| 24/08/2018 |
Notes to the Appendix 4E |
| 06/08/2018 |
Cleansing Notice and Appendix 3B |
| 06/08/2018 |
Notice of General Meeting |
| 31/07/2018 |
Cellmid Raised $9M via Share Placement |
| 31/07/2018 |
Notes to the Appendix 4C – Growing Consumer Health Sales Drive Revenue Uplift |
| 30/07/2018 |
Cellmid Share Purchase Plan |
| 27/07/2018 |
Trading Halt |
| 11/07/2018 |
Cellmid Updates on Distribution of evolis |
| 02/07/2018 |
Cellmid Investor Presentation July 2018 |
| 30/05/2018 |
5th Midkine Symposium Reinforces Clinical Potential for Cellmid’s Biotechnology Assets |
| 29/05/2018 |
Change of Address |
| 02/05/2018 |
Cellmid to Commence Selling evolis into Chinese Market |
| 24/04/2018 |
Cellmid Secures Bloomingdales USA Partnership for evolis |
| 23/04/2018 |
Appendix 4C – Quarterly |
| 10/04/2018 |
Cellmid Investor Presentation |
| 09/04/2018 |
Cellmid Convening 5th Midkine Symposium in Munich |
| 04/04/2018 |
Cellmid Signs Distribution Agreement for Fillerina |
| 29/03/2018 |
Change of Director’s Interest Notice – Halasz |
| 26/03/2018 |
Cellmid Appoints Dennis Eck Non-Executive Director |
| 26/03/2018 |
Initial Director’s Interest Notice – Eck |
| 14/03/2018 |
Change of Director’s Interest Notice – Halasz |
| 21/02/2018 |
Confirmation of Release – CDY – Appendix 4D and Half Year Accounts |
| 25/01/2018 |
Appendix 4C |
| 10/01/2018 |
Record $2M Quarterly Sales for Cellmid’s FGF5 Inhibitors |
| 09/01/2018 |
Cellmid Quarterly Operational update |
